secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENZO BIOCHEM INC (—)
CIK:        0000316253
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001213900-23-059242
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enzo Biochem closes clinical lab sale to Labcorp for $113.25M cash; exits lab business
--------------------------------------------------------------------------------

- Asset sale of Enzo Clinical Labs to Labcorp closed on July 24, 2023 for aggregate cash consideration of $113.25 million.
- Enzo will cease all clinical laboratory operations and focus on its life sciences business.
- Transaction was previously announced on March 16, 2023 and amended on July 3, 2023.
- Jefferies and McDermott Will & Emery advised Enzo; Evercore and Hogan Lovells advised Labcorp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/0001213900-23-059242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/316253/000121390023059242/ea182199-8k_enzobiochem.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-059242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer